Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma
- PMID: 12177239
- DOI: 10.1097/01.lab.0000024360.48464.a4
Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma
Abstract
The high incidence of HER2 overexpression on the cell surface of breast cancer cells and the recognized prognostic and potentially predictive value of HER2 render this cell surface receptor a novel and important therapeutic target. Although immunohistochemistry (IHC; HercepTest) and fluorescence in situ hybridization (FISH; PathVysion and INFORM)-both approved by the Food and Drug Administration-have emerged as the most viable assays for evaluation of HER2 status in routine clinical practice, there is still no consensus on which is the best method for assessing HER2 status. Therefore, our specific objective was to establish a chromogenic in situ hybridization (CISH) assay for the detection of HER2 amplification on a cohort of 173 archival invasive breast carcinomas. Results were compared with HercepTest, which is the most frequently used method for detecting HER2 alteration. Additionally, HER2 gene copy number was investigated using differential PCR (dPCR) as a testing system. HER2 overexpression was found by IHC in 24.3%; HER2 amplification was found by CISH in 19.1% and by dPCR in 9.2% of the tumors. The overall concordance rate was 95.9% between CISH and IHC and 85.0% between dPCR and IHC. Kappa statistics revealed an excellent agreement between IHC and CISH (kappa = 0.878), but only a moderate agreement was found between IHC and dPCR (kappa = 0.482). Discrepant cases between CISH and HercepTest and all IHC-positive cases (+2 and +3), a total of 42 cases, were analyzed with the FISH PathVysion (Vysis) assay. Among 25 HercepTest-positive cases (score +3), 2 showed no gene amplification by FISH or CISH. Four of 13 tumors with weak HER2 overexpression (score +2) were negative with both FISH and CISH. Concordance between CISH and FISH was 100% for the 38 cases analyzed. The current study showed that CISH represents a practical and simple assay for evaluating HER2 gene amplification in archival material, offering a promising alternative to IHC or FISH for the routine diagnostic setting.
Similar articles
-
Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.J Mol Histol. 2004 Aug;35(6):647-53. doi: 10.1007/s10735-004-2186-6. J Mol Histol. 2004. PMID: 15614619
-
Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.Mod Pathol. 2002 Jun;15(6):657-65. doi: 10.1038/modpathol.3880582. Mod Pathol. 2002. PMID: 12065780
-
HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):194-200. doi: 10.1097/01.pai.0000132189.01233.6d. Appl Immunohistochem Mol Morphol. 2005. PMID: 15894935
-
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Ann Pathol. 2011. PMID: 22172120 Review. French.
-
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.Braz J Med Biol Res. 2013 Mar;46(3):207-16. doi: 10.1590/1414-431x20132483. Epub 2013 Mar 19. Braz J Med Biol Res. 2013. PMID: 23558859 Free PMC article. Review.
Cited by
-
An update on the pathological classification of breast cancer.Histopathology. 2023 Jan;82(1):5-16. doi: 10.1111/his.14786. Histopathology. 2023. PMID: 36482272 Free PMC article. Review.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
Chromogenic in situ Hybridization Compared with Real time Quantitative Polymerase Chain Reaction to Evaluate HER2/neu Status in Breast Cancer.Iran J Pathol. 2017 Spring;12(2):128-134. Epub 2017 Apr 1. Iran J Pathol. 2017. PMID: 29515634 Free PMC article.
-
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.J Cancer. 2016 Jun 23;7(10):1281-94. doi: 10.7150/jca.13141. eCollection 2016. J Cancer. 2016. PMID: 27390604 Free PMC article. Review.
-
Molecular classification of breast cancer.Virchows Arch. 2014 Jul;465(1):1-14. doi: 10.1007/s00428-014-1593-7. Epub 2014 May 31. Virchows Arch. 2014. PMID: 24878755
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous